NasdaqGS - Delayed Quote USD

Precigen, Inc. (PGEN)

Compare
0.8986 +0.0641 (+7.68%)
At close: October 11 at 4:00 PM EDT
0.8900 -0.01 (-0.96%)
After hours: October 11 at 7:55 PM EDT
Loading Chart for PGEN
DELL
  • Previous Close 0.8345
  • Open 0.8500
  • Bid 0.8662 x 300
  • Ask 0.9295 x 500
  • Day's Range 0.8248 - 0.9022
  • 52 Week Range 0.8200 - 1.9300
  • Volume 506,656
  • Avg. Volume 1,011,064
  • Market Cap (intraday) 262.968M
  • Beta (5Y Monthly) 1.66
  • PE Ratio (TTM) --
  • EPS (TTM) -0.5400
  • Earnings Date Nov 7, 2024 - Nov 11, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 6.00

Precigen, Inc. operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar. The company offers therapeutic platforms consisting of UltraCAR-T to provide chimeric antigen receptor T cell therapies for cancer patients; AdenoVerse immunotherapy, which utilizes a library of proprietary adenovectors for gene delivery of therapeutic effectors, immunomodulators, and vaccine antigen; and ActoBiotics for specific disease modification. It also develops programs based on the UltraCAR-T platform, including PRGN-3005 in Phase 1b clinical trial to treat advanced ovarian, fallopian tube, or primary peritoneal cancer; PRGN-3006 in Phase 1b trial for patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndromes; and PRGN-3007 in Phase 1/1b trial for the treatment of advanced receptor tyrosine kinase-like orphan receptor 1-positive, hematologic, and solid tumors. In addition, the company is developing programs based on the AdenoVerse immunotherapy platform comprising PRGN-2009 in Phase 2 trial for patients with HPV-associated cancer; and PRGN-2012 in Phase ? trial to treat recurrent respiratory papillomatosis, as well as AG019, which is based on the ActoBiotics platform and in Phase 1b/2a trial, to treat type 1 diabetes mellitus. Further, it provides UltraPorator, a proprietary electroporation device; and develops research models and services for healthcare research applications. The company was formerly known as Intrexon Corporation and changed its name to Precigen, Inc. in February 2020. Precigen, Inc. was founded in 1998 and is headquartered in Germantown, Maryland.

precigen.com

202

Full Time Employees

December 31

Fiscal Year Ends

Recent News: PGEN

View More

Performance Overview: PGEN

Trailing total returns as of 10/11/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

PGEN
32.94%
S&P 500
21.91%

1-Year Return

PGEN
23.20%
S&P 500
33.43%

3-Year Return

PGEN
80.76%
S&P 500
32.42%

5-Year Return

PGEN
84.48%
S&P 500
97.92%

Compare To: PGEN

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: PGEN

View More

Valuation Measures

Annual
As of 10/11/2024
  • Market Cap

    262.97M

  • Enterprise Value

    249.77M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    51.14

  • Price/Book (mrq)

    6.09

  • Enterprise Value/Revenue

    56.91

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -42.32%

  • Return on Equity (ttm)

    -129.32%

  • Revenue (ttm)

    4.39M

  • Net Income Avi to Common (ttm)

    -135.38M

  • Diluted EPS (ttm)

    -0.5400

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    19.54M

  • Total Debt/Equity (mrq)

    14.69%

  • Levered Free Cash Flow (ttm)

    -45.84M

Research Analysis: PGEN

View More

Earnings Per Share

Consensus EPS
 

Revenue vs. Earnings

Revenue 1.06M
Earnings -23.74M
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Analyst Price Targets

4.00
6.00 Average
0.8986 Current
7.00 High
 

Company Insights: PGEN

People Also Watch